A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
← catalyst calendarNCT05791201 · readout in 205 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
7actual
Sites
16
Countries
Canada, Germany, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-16 | actual | When the study began enrolling |
| Primary completion | 2027-03-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-12 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes
Intervention
- Drug: VX-264
Primary outcomes
what the primary-completion date above is the date OFPart A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From Day 1 up to 24 months
Part B: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT)
measured From Baseline and at Day 90
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed